Dorotheé von Laer

Innsbruck Medical University — Austria

Biochemistry, Genetics and Molecular Biology · Life Sciences

51h-index8.1kcitations260works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(96), SARS-CoV-2 and COVID-19 Research(64), HIV Research and Treatment(45), CAR-T cell therapy research(40), Animal Virus Infections Studies(33)

Publications259 total

Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits
npj Vaccines·2025Open Access
Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patterns
Vaccine·2025· 2 citedOpen Access
Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy
Journal of Virology·2025· 1 citedOpen Access
Changes in self-reported physical and mental health, behaviour and economic status among adults by known seropositivity and sociodemographic factors before and after the COVID-19 pandemic outbreak in Ischgl, Austria
Frontiers in Public Health·2025Open Access
Using Vesicular Stomatitis Virus as a Platform for Directed Protease Evolution
Current Protocols·2024· 1 citedOpen Access
Vesicular Stomatitis Virus as a Platform for Protease Activity Measurements
Current Protocols·2024· 1 citedOpen Access
Disproportionate preponderance of HPV genotypes associated with anogenital warts among HIV-positive MSM
Frontiers in Public Health·2024· 3 citedOpen Access
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system
PLoS Pathogens·2024· 10 citedOpen Access
Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system
Antiviral Research·2024· 9 citedOpen Access
Terminal Ileitis as the Exclusive Manifestation of COVID-19 in Children
Microorganisms·2024· 1 citedOpen Access
Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir
npj Viruses·2024· 13 citedOpen Access
TOP-359-YI Development of a replication-competent Vesicular Stomatitis Virus (VSV) vector for therapeutic hepatitis B vaccination
Journal of Hepatology·2024
Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
npj Vaccines·2024· 9 citedOpen Access
Machine Learning to Identify Critical Biomarker Profiles in New SARS-CoV-2 Variants
Microorganisms·2024· 1 citedOpen Access
Detection of infectious SARS-CoV-2 in ocular samples is linked to viral load in the nasopharynx
Frontiers in Cellular and Infection Microbiology·2024· 3 citedOpen Access
Highly Specific Sars-Cov-2 Main Protease (Mpro) Mutations Against the Clinical Antiviral Ensitrelvir Selected in a Safe, Vsv-Based System
SSRN Electronic Journal·2024· 2 citedOpen Access
Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
2023· 1 citedOpen Access
Identification of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir
2023· 2 citedOpen Access
Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster
The Journal of Infectious Diseases·2023· 1 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Janine Kimpel(11), Tsanan Giroglou(7), Wegene Borena(5), Annika Rössler(5), Christopher Baum(4), Boris Fehse(4), Hrvoje Miletić(4), Alexander Muik(4), Frank T. Hufert(4), Ursula Meyer‐König(4), Sebastian Newrzela(3), Ulrike Koehl(3), Gunda Brandenburg(3), Christel Baum(3), Lisa Egerer(3), Reinhard Tober(3), Lydia Riepler(3), André Volland(3), David Bante(3), Otto Haller(3)